Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation

Current Problems in Cancer: Case Reports

Caitlyn Cummings¹  Billie Radovic²  Lubaina Presswala³  Ronald Rosen⁴ 

[1] Corresponding author.;Department of Medicine, Long Island Jewish Medical Center, 755 North Broadway, Suite 100, Sleepy Hollow, Hyde Park, New York, United States;Department of Pharmacy, Long Island Jewish Medical Center, New Hyde Park, New York, United States;Division of Endocrinology, Diabetes and Metabolism, Long Island Jewish Medical Center, New Hyde Park, New York, United States;

关键词: Adjuvant hormonal therapy;    Breast cancer;    Diabetes;    Tamoxifen;    Hyperglycemic hyperosmolar state;   

DOI  :  

来源: DOAJ

【 摘 要 】

Selective estrogen receptor modulators, such as tamoxifen, have been used for many years to reduce the recurrence of breast cancer. There is limited data on tamoxifen use in males with breast cancer. Hyperglycemia or risk of diabetes is not listed on the package insert for tamoxifen. In this clinical case, one patient presented with hyperosmolar hyperglycemic state two months after starting tamoxifen for male breast cancer. Discontinuation of tamoxifen resulted in decreased hemoglobin A1c levels back to baseline and rebound of C- peptide levels.

【 授权许可】

Unknown